Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression

Seiya Sato, Hiroaki Itamochi, Nao Oumi, Youhei Chiba, Tetsuro Oishi, Muneaki Shimada, Shinya Sato, Jun Chikumi, Michiko Nonaka, Akiko Kudoh, Hiroaki Komatsu, Tasuku Harada, Toru Sugiyama

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


A new cell line of human ovarian clear cell carcinoma (CCC), TU-OC-2, was established and characterized. The cells were polygonal in shape, grew in monolayers without contact inhibition and were arranged in islands like pieces of a jigsaw puzzle. The chromosome numbers ranged from 41 to 96. A low rate of proliferation was observed and the doubling time was 37.5 h. The IC50 values of cisplatin, 7-ethyl-10-hydroxycamptothecin (SN38), which is an active metabolite of camptothecin, and paclitaxel were 7.7 μM, 17.7 nM and 301 nM, respectively. The drug sensitivity assay indicated that TU-OC-2 was sensitive to SN38, but resistant to cisplatin and paclitaxel. Mutational analysis revealed that TU-OC-2 cells have no mutations of PIK3CA in exons 9 and 20 and of TP53 in exons 4–9. We observed the loss of ARID1A protein expression in TU-OC-2 cells by western blot analysis and in the original tumor tissue by immunohistochemistry. This cell line may be useful for studying the chemoresistant mechanisms of CCC and exploring novel therapeutic targets such as the ARID1A-related signaling pathway.

Original languageEnglish
Pages (from-to)181-187
Number of pages7
JournalHuman Cell
Issue number4
Publication statusPublished - 2016 Oct 1
Externally publishedYes


  • ARID1A
  • Chemosensitivity
  • Establishment
  • Molecular-targeted therapy
  • Ovarian clear cell carcinoma

ASJC Scopus subject areas

  • Cell Biology
  • Cancer Research


Dive into the research topics of 'Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression'. Together they form a unique fingerprint.

Cite this